Myocardial fibrosis predicts ventricular arrhythmias and sudden death after cardiac electronic device implantation.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Leyva, FranciscoZegard, Abbasin
Okafor, Osita
Foley, Paul
Umar, Fraz
Taylor, Robin J
Marshall, Howard
Stegemann, Berthold
Moody, William
Steeds, Richard P
Halliday, Brian P
Hammersley, Daniel J
Jones, Richard E
Prasad, Sanjay K
Qiu, Tian
Publication date
2022-02-22Subject
Cardiology
Metadata
Show full item recordAbstract
Background: Increasing evidence supports a link between myocardial fibrosis (MF) and ventricular arrhythmias. Objectives: The purpose of this study was to determine whether presence of myocardial fibrosis on visual assessment (MFVA) and gray zone fibrosis (GZF) mass predicts sudden cardiac death (SCD) and ventricular fibrillation/sustained ventricular tachycardia after cardiac implantable electronic device (CIED) implantation. Methods: In this prospective study, total fibrosis and GZF mass, quantified using cardiovascular magnetic resonance, was assessed in relation to the primary endpoint of SCD and the secondary, arrhythmic endpoint of SCD or ventricular arrhythmias after CIED implantation. Results: Among 700 patients (age 68.0 ± 12.0 years), 27 (3.85%) experienced a SCD and 121 (17.3%) met the arrhythmic endpoint over median 6.93 years (IQR: 5.82-9.32 years). MFVA predicted SCD (HR: 26.3; 95% CI: 3.7-3,337; negative predictive value: 100%). In competing risk analyses, MFVA also predicted the arrhythmic endpoint (subdistribution HR: 19.9; 95% CI: 6.4-61.9; negative predictive value: 98.6%). Compared with no MFVA, a GZF mass measured with the 5SD method (GZF5SD) >17 g was associated with highest risk of SCD (HR: 44.6; 95% CI: 6.12-5,685) and the arrhythmic endpoint (subdistribution HR: 30.3; 95% CI: 9.6-95.8). Adding GZF5SD mass to MFVA led to reclassification of 39% for SCD and 50.2% for the arrhythmic endpoint. In contrast, LVEF did not predict either endpoint. Conclusions: In CIED recipients, MFVA excluded patients at risk of SCD and virtually excluded ventricular arrhythmias. Quantified GZF5SD mass added predictive value in relation to SCD and the arrhythmic endpoint.Citation
Leyva F, Zegard A, Okafor O, Foley P, Umar F, Taylor RJ, Marshall H, Stegemann B, Moody W, Steeds RP, Halliday BP, Hammersley DJ, Jones RE, Prasad SK, Qiu T. Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. J Am Coll Cardiol. 2022 Feb 22;79(7):665-678. doi: 10.1016/j.jacc.2021.11.050Type
ArticleAdditional Links
https://www.sciencedirect.com/journal/journal-of-the-american-college-of-cardiologyPMID
35177196Publisher
Elsevier Biomedicalae974a485f413a2113503eed53cd6c53
10.1016/j.jacc.2021.11.050